Aurora-A(C-term)(AURKA)antibody
Cat.#: 1800-1
Rabbit Monoclonal Antibody
Clone ID: EP1008Y
Swiss Prot: O14965
Mol Weight: 46kDa
Size: 100ul

Description
Aurora-A is a member of a novel family of serine/threonine kinases that have been identified as key regulators of the mitotic cell division process (1). Aurora-A is ubiquitously expressed and activated through an interaction with Ajuba and TPX2 during late G2 and mitotic phases. Activated form regulates the functions of centrosomes, spindles, and kinetochores required for normal mitotic progression. Initially localized at centrosome during interphase, Aurora-A is translocated to mitotic spindles in early mitotic phase and finally degraded after metaphase/anaphase transition (2). Overexpression of Aurora-A is seen various tumors, where overexpression can induce abnormalities in G2 and spindle checkpoints, and cytokinesis failure (3).

Recommended Applications
WB, IHC, IP

Applications and Recommended Dilution Factors
WB: 1:1,000 - 10,000
IHC: 1:100-250
IP: 1:50

Species Reactivity
Human

Cross reactivity determined by western blot only.

Products Data 

 

A. Western blot analysis on HepG2 lysate using anti-Aurora-A RabMAb (cat. # 1800-1).
B. Immunohistochemical analysis of paraffin-embedded human cervical carcinoma using anti-Aurora-A RabMAb (cat# 1800-1)

Specificity
A synthetic peptide corresponding to residues near the C-terminus of human Aurora-A was used as an immunogen.

Storage Condition and Buffer
Store at -20 °C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.

Alternative Names
AURKA antibody, AIK antibody, ARK1 antibody, AURA antibody, AURORA2 antibody, BTAK antibody, MGC34538 antibody, STK15 antibody, STK6 antibody, STK7 antibody, Serine/threonine-protein kinase 6 antibody, Breast tumor-amplified kinase antibody, Serine/threonine-protein kinase 15 antibody, Serine/threonine-protein kinase aurora-A antibody

Description References
1. Katayama H, et al. Cancer Metastasis Rev. 22(4): 451-64, 2003
2. Duct D et al, Exp Cell Res. 15;301(1):60-7, 2004.
3. Murimoto T et al, Nat Rev Cancer. Jan;5(1):42-50, 2005.

Product References
1. Fiskus W, Wang Y, Joshi R, et al, Co-treatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells ,Clin Cancer Res. 14 (2008) 6106-6115
[Application: WB]